Related Experiment Video
Updated: Jun 4, 2025
06:18
Author Spotlight: Advancements in CAR-T Cell Manufacturing and Gene Therapy Production
Published on: August 18, 2023
2.4K
Accelerating CAR T cell manufacturing with an automated next-day process
Moloud Ahmadi1, Nicholas Putnam1, Max Dotson1
1Thermo Fisher Scientific, 5781 Van Allen Way, Carlsbad CA 92008, USA.
Current Research in Translational Medicine
|December 20, 2024
Summary
A new 24-hour CAR T cell manufacturing process preserves vital naive T cells, enhancing therapy effectiveness and patient access. This streamlined method improves CAR T cell production efficiency and potential clinical outcomes.
Area of Science:
- Immunotherapy
- Cellular Therapy
- Biotechnology
Background:
- Traditional CAR T cell production requires lengthy ex-vivo culture, depleting essential naive T cell subsets.
- Extended manufacturing times delay patient treatment, potentially worsening disease progression.
Purpose of the Study:
- To develop an innovative, semi-automated 24-hour manufacturing process for CAR T cells.
- To evaluate the impact of the rapid process on T cell subsets and in vitro function.
Main Methods:
- A novel semi-automated 24-hour manufacturing protocol for CAR T cells was established.
- In vitro assays were performed to assess cytotoxic activity and cytokine release of manufactured CAR T cells.
Main Results:
- The 24-hour process yielded a higher percentage of naive/stem-cell like T cells compared to traditional methods.
- Manufactured CAR T cells demonstrated potent cytotoxic activity and significant cytokine release in vitro.
Conclusions:
- The streamlined 24-hour CAR T manufacturing process is feasible for clinical implementation.
- This innovative approach has the potential to improve CAR T therapy efficacy and patient accessibility.
